Language selection

Search


Guidance for clinical trials with decentralized elements.: H169-14/2026E-PDF

"This guidance outlines regulatory considerations for conducting clinical trials with decentralized elements in Canada. These considerations are supported by Part C, Division 5 of the Food and Drug Regulations (FDR) and the International Council for Harmonisation’s Guideline for Good Clinical Practice (ICH E6)"--Overview, Purpose, page 1.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.967064&sl=0

Publication information
Department/Agency
  • Canada. Health Canada, issuing body.
  • Canada. Pharmaceutical Drugs Directorate, issuing body.
  • Canada. Biologic and Radiopharmaceutical Drugs Directorate, issuing body.
TitleGuidance for clinical trials with decentralized elements.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Title from cover.
  • Issued also in French under title: Lignes directrices pour les essais cliniques avec des éléments décentralisés.
  • "Health products."
  • Includes bibliographical references (pages 50-51).
Publishing information
  • Ottawa ON : Health Canada = Santé Canada, October 2026.
  • ©2026
Description1 online resource (iii, 52 pages)
ISBN9781100010700
Catalogue number
  • H169-14/2026E-PDF
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details